Developer docs
API playgroundTry for free, no card

Search company profiles

iNtRON Biotechnology

Full company profile

uuid0029vrw

Namestring
iNtRON Biotechnology
Legal namestring
iNtRON Biotechnology, Inc.
Websiteurl
intodeworld.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

iNtRON Biotechnology is a KOSDAQ-listed South Korean biopharmaceutical company headquartered in Seongnam-si, Gyeonggi-do, founded in 2000 by CEO Kyung Won Yoon. The company operates two business parts: a New Drug Part focused on bacteriophage- and endolysin-based therapeutics, and a Diagnostics & Reagents (DR) Part that develops and commercializes molecular diagnostic kits. The New Drug Part is built on two proprietary platforms — itLysin® (engineered endolysin technology enhanced via advanced bio-engineering for first-in-class antimicrobial resistance therapeutics) and IMPA™ (Intelligent Modular Phage Assembly, integrating CRISPR/Cas and transposon mutagenesis with AI-driven analytics to engineer modular bacteriophages for immunotherapeutics and vaccines) — supported by complementary platforms PHAGERIA®, PHAGERUS®, and PHAGERIARUS® targeting microbiome-immunity modulation, virus-targeted vaccines, and direct phage-immune interactions, respectively. The pipeline is anchored by SAL200 [INT-211] (lead endolysin candidate for infective endocarditis and bacteremia, US FDA Phase 2b IND-approved) and spans nasal decolonization (INT-214, MFDS Phase 1/2a IND-approved June 2026), CRE decolonization (PKL200), oncology candidates (TgC-Phage E, TgG-Phage E), agricultural applications (EAL2200 for fire blight), and veterinary indications (bovine mastitis, African Swine Fever).

The company's go-to-market is bifurcated. On the therapeutics side, it pursues global out-licensing and co-development partnerships — most notably the 2018 Roivant Sciences agreement for SAL200 worth up to US$667.5M in milestone payments plus low double-digit royalties on net sales, with options for additional anti-Gram-positive programs and first right of offer on anti-Gram-negative assets. Business development is conducted through direct enterprise engagement and major industry events (e.g., BIO USA 2026 in San Diego). On the diagnostics and reagents side, the LiliF™ brand commercializes molecular diagnostic kits (COVID-19 IgG rapid kit, avian influenza H5/H7/H9, nucleic acid extraction reagents with EU CE-IVDR certification) and veterinary bacteriophage alternatives for livestock and aquaculture markets. Customers and collaborators span global pharmaceutical licensing partners (Roivant Sciences), government/defense (U.S. Army DEVCOM), clinical and academic centers (Seoul National University Hospital for INT-214 trials; Seoul National University Cancer Research Institute for colorectal cancer phage studies), and end-buyers of diagnostic and veterinary products. Recent strategic actions include the June 2025 launch of a Scientific Advisory Board chaired by Prof. Hong Bin Kim (WHO STAG-AMR member) and the September 2025 establishment of an Anti-Cancer Immunology division led by Dr. Jangjun Park (ex-Johns Hopkins). The differentiated scientific moat is reinforced by 365+ intellectual property records, 39+ peer-reviewed publications, and a proprietary database of 11,800+ phage genomic sequences and 677+ whole-genome sequences underpinning candidate selection and engineering.

Short descriptiontext

iNtRON Biotechnology is a KOSDAQ-listed South Korean biopharmaceutical company developing first-in-class bacteriophage- and endolysin-based therapeutics (itLysin®, IMPA™) for antimicrobial resistance, oncology, and vaccines, alongside a LiliF™ molecular diagnostics and reagents business. It monetizes via global out-licensing partnerships (Roivant Sciences for SAL200) and direct diagnostics/veterinary product sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bacteriophage therapeutics, endolysin platform, antimicrobial resistance drugs, molecular diagnostic kits, phage engineering platform
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceuticals — Bacteriophage and Endolysin Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Royalties
TypeLicensing Royalties
Description

Out-licensing of early-stage novel pipelines including SAL200 to global pharmaceutical companies. In 2018, signed global licensing agreement with Roivant Sciences worth US$667.5M inclusive of milestone payments, with royalties on net sales in low double digits. Active pursuit of out-licensing opportunities for endolysin pipelines and IMPA-based immuno-oncology agents.

intodeworld.com
2Molecular Diagnostics Products
TypeHardware Sales
Description

Revenue from development and commercialization of molecular diagnostic kits for animal and human infectious diseases including COVID-19 diagnostic kits, avian influenza tests, and other PCR/qPCR-based diagnostics. Also received CE-IVDR certification for nucleic acid automatic extraction reagent.

intodeworld.com
3Veterinary Antibiotic Alternatives
TypeOne Time License
Description

Commercialized animal antibiotic alternatives using natural bacteriophages to address issues associated with synthetic veterinary antibiotics, generating stable revenue from livestock and aquaculture markets.

intodeworld.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1itLysin
Description

Proprietary endolysin engineering platform technology for developing engineered endolysins as smart therapeutics for antimicrobial resistance (AMR)

intodeworld.com
+6 more records
Core offering1 text field

iNtRON Biotechnology develops and commercializes bacteriophage- and endolysin-based biopharmaceuticals through two proprietary platform technologies: itLysin® (engineered endolysin therapeutics) and IMPA™ (modular bacteriophage engineering for immunotherapeutics and vaccines). The company also develops and sells the LiliF™ line of molecular diagnostic kits for human and animal infectious diseases and veterinary bacteriophage-based antibiotic alternatives.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

iNtRON Biotechnology is a novel drug development company operating two core divisions: a New Drug Part focused on biopharmaceutical development, and a DR (Diagnostics & Reagents) Part generating current revenue through molecular diagnostic kits. The New Drug Part centers on two proprietary platform technologies: itLysin®, an engineered endolysin platform for First-in-Class anti-infectives targeting antimicrobial resistance (AMR), and IMPA™, a bacteriophage engineering platform enabling First-in-Concept immunotherapeutics and vaccines for oncology and infectious diseases. The lead pipeline SAL200 [INT-211] has advanced to US FDA Phase 2b for infective endocarditis, while SAL200 [INT-214] nasal decolonization received MFDS Phase 1/2a IND approval. Additional pipelines span CRE decolonization (PKL200), colorectal cancer (TgC-Phage E), GLP-1 delivery (TgG-Phage E), ASF vaccine, and agricultural applications (EAL2200 for fire blight). The company also operates the LiliF™ diagnostic kit brand and holds supporting platforms including PHAGERIA®, PHAGERUS®, and PHAGERIARUS® for microbiome-based immunotherapeutics.

Product and service16 records
1itLysin® Platform (Engineered Endolysin Therapeutics)
CategoryBiopharmaceutical Platform Technology
Description

Proprietary endolysin-engineering platform that develops engineered bacteriophage-derived lysins enhanced through advanced bio-engineering to overcome superbugs with superior activity, stability, and safety. Targeted at pharmaceutical partners for licensing and clinical co-development.

2IMPA™ (Intelligent Modular Phage Assembly) Platform
CategoryBiopharmaceutical Platform Technology
Description

Bacteriophage engineering platform that integrates transposon mutagenesis, CRISPR/Cas-based editing, and AI-driven analytics to develop modular phages displaying target proteins on capsids or outer surfaces, enabling dual-targeting therapeutics (bactericidal activity combined with functional protein effects) for immuno-oncology and vaccine applications.

3SAL200 [INT-211] Drug Candidate
CategoryDrug Candidate (Anti-Infective)
Description

Lead itLysin®-derived endolysin drug candidate for treatment of infective endocarditis and bacteremia caused by MRSA, VRSA, and CoNS. Holds US FDA Phase 2b IND approval and demonstrated 67- to 267-fold higher antibacterial activity than competing candidates in University of Barcelona research.

4SAL200 [INT-214] Nasal Decolonization Drug Candidate
CategoryDrug Candidate (Anti-Infective)
Description

Nasal SAL200 formulation for pre-operative Staphylococcus aureus decolonization to prevent hospital-acquired infections. MFDS Phase 1/2a IND approved, with clinical site designated at Seoul National University Hospital.

5PKL200 [INT-223] CRE Decolonization Drug Candidate
CategoryDrug Candidate (Anti-Infective)
Description

Engineered endolysin candidate for intestinal Carbapenem-Resistant Enterobacteriaceae (CRE) decolonization aimed at preventing superbug spread.

6BAL200 (N-Rephasin®) Anthrax Treatment
CategoryDrug Candidate (Anti-Infective / Biodefense)
Description

Endolysin-based biologic for treatment of inhalational anthrax infection by Bacillus anthracis; received US FDA Orphan Drug Designation providing 7-year market exclusivity, tax credits, and fee waivers.

7TgC-Phage E Colorectal Cancer Therapeutic
CategoryDrug Candidate (Oncology)
Description

IMPA™-engineered bacteriophage targeting colorectal cancer-associated bacteria (ETBF and pks+ E. coli) using a dual mechanism of bacterial eradication plus genotoxin neutralization. Preclinical proof-of-concept stage.

8SSL2200 [INT-262] Bovine Mastitis Treatment
CategoryVeterinary Drug Candidate
Description

Engineered endolysin-based treatment for bovine mastitis providing an antibiotic alternative for livestock veterinary applications.

9EAL2200 Fire Blight Treatment Candidate
CategoryAgricultural Biologics
Description

Endolysin candidate (EAL2200) for agricultural fire blight prevention and treatment in apple and pear orchards, achieving 100% eradication of all three Erwinia amylovora target strains at 10 μg/mL via an ultra-rapid lytic mechanism. Produced via the Spirulina microalgae platform with 16.5-fold higher productivity than E. coli. Patent filed July 2025.

10GN200 [INT-001] Gram-Negative Antibacterial Candidate
CategoryDrug Candidate (Anti-Infective)
Description

Broad-spectrum gram-negative antibacterial drug candidate targeting resistant gram-negative bacteria for antimicrobial resistance applications.

11AgASF-Phage E African Swine Fever Vaccine Candidate
CategoryVeterinary Vaccine Candidate
Description

IMPA™ platform-based vaccine candidate for African Swine Fever, targeted at the global animal health market.

12TgG-Phage E GLP-1 Agonist Candidate
CategoryDrug Candidate (Metabolic)
Description

IMPA™ modular phage platform candidate delivering a GLP-1 agonist short peptide for targeted obesity/metabolic disease therapy, demonstrating the platform's extension beyond full-length proteins.

13pHyal20 (Hyal20-Phage) Drug Delivery Platform
CategoryDrug Delivery Platform
Description

Hyaluronidase phage platform (pHyal20) for subcutaneous injection drug delivery enhancement, designed to improve subcutaneous bioavailability.

14LiliF™ Molecular Diagnostic Kits
CategoryIn-Vitro Diagnostics (Molecular Diagnostics)
Description

Brand of molecular diagnostic kits for human and animal infectious disease detection, including the LiliF™ GBN COVID-19 IgG Rapid Kit (lateral flow immunoassay for anti-SARS-CoV-2 IgG antibodies), avian influenza H5/H7/H9 tests, and bovine blackleg detection assays. Distributed directly and through a commercial subsidiary.

15CE-IVDR Certified Nucleic Acid Extraction Reagent
CategoryIn-Vitro Diagnostics Reagent
Description

EU CE-IVDR certified reagent for automatic nucleic acid extraction, providing iNtRON a regulatory pathway for diagnostic products into the European Union market.

16Spirulina (Arthrospira platensis) Recombinant Protein Production Platform
CategoryBiomanufacturing Platform
Description

Proprietary microalgae-based (Arthrospira platensis / Spirulina) recombinant protein production platform delivering up to 35.3-fold higher yields than conventional E. coli expression, with the additional ability for Spirulina's cell wall to act as natural encapsulation for whole-cell products. Spirulina has US FDA GRAS status.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Seoul National University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Designated clinical trial site for Phase 1/2a clinical studies of Nasal SAL200 (INT-214) nasal decolonization drug candidate. Company is working closely with the hospital to initiate clinical studies for Staphylococcus aureus decolonization indication.

intodeworld.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Research collaboration for IMPA™ phage efficacy studies against colorectal cancer-associated bacteria (ETBF and pks+ E. coli) using human colon organoid models. Study accepted for publication in Scientific Reports journal, demonstrating therapeutic effects of bacteriophages targeting cancer-associated pathogens.

3Dr. Jangjun Park (Johns Hopkins University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Recruited anticancer immunology expert from Professor Drew Pardoll's team at Johns Hopkins University. Dr. Park has 25+ years of experience in cancer immunology with publications in Nature, and experience at Arbutus Biopharma and ISU Abxis. Appointed as Executive Director and head of ACI (anticancer immunology) business division to lead clinical development using IMPA™ platform technology.

intodeworld.com
4Prof. Hong Bin Kim (Seoul National University Bundang Hospital)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Appointed as Scientific Advisory Board (SAB) Chair for AMR Committee. Prof. Kim is a world-renowned expert in antimicrobial resistance and member of WHO Strategic and Technical Advisory Group on AMR (STAG-AMR). Provides guidance on clinical development and commercialization of itLysin (endolysin) therapeutics.

intodeworld.com
5U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Bacteriophage development project for urinary tract infections (UTI) targeting E. coli in soldiers. Collaboration leverages iNtRON's bacteriophage technology for military healthcare applications. Featured in major news outlets including The Wall Street Journal, Bloomberg, and Clinical Trials Arena.

intodeworld.com
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-20
Description

Global licensing agreement for SAL200, a novel investigational biologic for treatment of antibiotic-resistant staphylococci infections. Deal worth US$667.5M inclusive of milestone payments, with royalties on net sales in low double digits. Includes option for Roivant to license additional anti-Gram-positive endolysin programs (anti-VRE, anti-TB biologics) for up to US$45M each, and first right of offer for anti-Gram-negative platform. Roivant created dedicated subsidiary for global development and commercialization.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Locus Biosciences develops engineered phage products using CRISPR-Cas3 payloads to target antibiotic-resistant bacteria. While focused more on engineered phage payloads than endolysins, it overlaps with iNtRON's IMPA platform's modular payload concept for dual-action antibacterial therapeutics.

TypeEmerging player
Description

Eligo Bioscience develops engineered phages (eligobiotics) carrying CRISPR payloads to precisely edit microbiome gene expression. It is comparable to iNtRON's IMPA platform in pursuing programmable phage-based precision therapeutics, though with a different delivery mechanism.

TypeDirect peer
Description

Adaptive Phage Therapeutics is a clinical-stage phage therapy company focused on personalized phage treatment for antibiotic-resistant bacterial infections, including a partnership with the US Department of Defense for military wound infections. It is a direct peer to iNtRON's bacteriophage programs including the US Army DEVCOM UTI project.

TypeDirect peer
Description

ContraFect is a US-based clinical-stage biotechnology company developing direct lytic agents (endolysins) for serious bacterial infections including MRSA bacteremia. It is the closest direct competitor to iNtRON's SAL200/itLysin platform and the most referenced endolysin peer in the AMR space.

TypeOthers
Description

Roivant Sciences is the strategic licensing partner that signed the US$667.5M SAL200 deal with iNtRON in 2018. It is included as an ecosystem participant/customer rather than a competitor, but represents the most important commercial relationship for iNtRON's lead asset and a structural reference point for any future platform out-licensing transactions.

TypeDirect peer
Description

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails for indications including inflammatory bowel disease and colorectal cancer-associated bacteria. Its microbiome-phage approach for oncology and infectious diseases overlaps directly with iNtRON's PHAGERIA and TgC-Phage E programs.

TypeRegional player
Description

Pherecydes Pharma is a French clinical-stage company developing phage therapy for resistant bacterial infections, including bone-and-joint and burn wound infections. It is a regional (European) phage therapy peer that competes in similar indications to some iNtRON programs.

TypeEmerging player
Description

Micreos develops endolysin-based products including Gladskin (over-the-counter endolysin for skin conditions) and food-safety phage products. While more commercial-stage and consumer-facing, it is comparable to iNtRON's endolysin and veterinary phage (SSL2200, EAL2200) product strategies.

9Seegene
TypeRegional player
Description

Seegene is a major South Korean molecular diagnostics company specializing in multiplex PCR-based diagnostic kits, directly comparable to iNtRON's LiliF molecular diagnostic product line for infectious diseases. Same geography (Korea) and same core technology (PCR/qPCR diagnostics).

TypeDirect peer
Description

Armata Pharmaceuticals develops engineered bacteriophage-based therapies for antibiotic-resistant infections, including Staphylococcus aureus bacteremia. Both Armata and iNtRON compete in phage/endolysin-based antimicrobial therapeutics, making Armata a direct modality peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iNtRON Biotechnology

Biopharmaceuticals — Bacteriophage and Endolysin Therapeuticsintodeworld.com

iNtRON Biotechnology is a KOSDAQ-listed South Korean biopharmaceutical company developing first-in-class bacteriophage- and endolysin-based therapeutics (itLysin®, IMPA™) for antimicrobial resistance, oncology, and vaccines, alongside a LiliF™ molecular diagnostics and reagents business. It monetizes via global out-licensing partnerships (Roivant Sciences for SAL200) and direct diagnostics/veterinary product sales.

What iNtRON Biotechnology does

iNtRON Biotechnology is a KOSDAQ-listed South Korean biopharmaceutical company headquartered in Seongnam-si, Gyeonggi-do, founded in 2000 by CEO Kyung Won Yoon. The company operates two business parts: a New Drug Part focused on bacteriophage- and endolysin-based therapeutics, and a Diagnostics & Reagents (DR) Part that develops and commercializes molecular diagnostic kits. The New Drug Part is built on two proprietary platforms — itLysin® (engineered endolysin technology enhanced via advanced bio-engineering for first-in-class antimicrobial resistance therapeutics) and IMPA™ (Intelligent Modular Phage Assembly, integrating CRISPR/Cas and transposon mutagenesis with AI-driven analytics to engineer modular bacteriophages for immunotherapeutics and vaccines) — supported by complementary platforms PHAGERIA®, PHAGERUS®, and PHAGERIARUS® targeting microbiome-immunity modulation, virus-targeted vaccines, and direct phage-immune interactions, respectively. The pipeline is anchored by SAL200 [INT-211] (lead endolysin candidate for infective endocarditis and bacteremia, US FDA Phase 2b IND-approved) and spans nasal decolonization (INT-214, MFDS Phase 1/2a IND-approved June 2026), CRE decolonization (PKL200), oncology candidates (TgC-Phage E, TgG-Phage E), agricultural applications (EAL2200 for fire blight), and veterinary indications (bovine mastitis, African Swine Fever).

The company's go-to-market is bifurcated. On the therapeutics side, it pursues global out-licensing and co-development partnerships — most notably the 2018 Roivant Sciences agreement for SAL200 worth up to US$667.5M in milestone payments plus low double-digit royalties on net sales, with options for additional anti-Gram-positive programs and first right of offer on anti-Gram-negative assets. Business development is conducted through direct enterprise engagement and major industry events (e.g., BIO USA 2026 in San Diego). On the diagnostics and reagents side, the LiliF™ brand commercializes molecular diagnostic kits (COVID-19 IgG rapid kit, avian influenza H5/H7/H9, nucleic acid extraction reagents with EU CE-IVDR certification) and veterinary bacteriophage alternatives for livestock and aquaculture markets. Customers and collaborators span global pharmaceutical licensing partners (Roivant Sciences), government/defense (U.S. Army DEVCOM), clinical and academic centers (Seoul National University Hospital for INT-214 trials; Seoul National University Cancer Research Institute for colorectal cancer phage studies), and end-buyers of diagnostic and veterinary products. Recent strategic actions include the June 2025 launch of a Scientific Advisory Board chaired by Prof. Hong Bin Kim (WHO STAG-AMR member) and the September 2025 establishment of an Anti-Cancer Immunology division led by Dr. Jangjun Park (ex-Johns Hopkins). The differentiated scientific moat is reinforced by 365+ intellectual property records, 39+ peer-reviewed publications, and a proprietary database of 11,800+ phage genomic sequences and 677+ whole-genome sequences underpinning candidate selection and engineering.

iNtRON Biotechnology firmographics

Firmographics
Name
iNtRON Biotechnology
Legal name
iNtRON Biotechnology, Inc.
Website
https://intodeworld.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
iNtRON Biotechnology is a KOSDAQ-listed South Korean biopharmaceutical company developing first-in-class bacteriophage- and endolysin-based therapeutics (itLysin®, IMPA™) for antimicrobial resistance, oncology, and vaccines, alongside a LiliF™ molecular diagnostics and reagents business. It monetizes via global out-licensing partnerships (Roivant Sciences for SAL200) and direct diagnostics/veterinary product sales.
Ownership category
akta.pro rank

iNtRON Biotechnology industry classification

Industry
Product category
Biopharmaceuticals — Bacteriophage and Endolysin Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Bacteriophage therapeutics
  • Endolysin platform
  • Antimicrobial resistance drugs
  • Molecular diagnostic kits
  • Phage engineering platform

Where iNtRON Biotechnology is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

iNtRON Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Royalties: Out-licensing of early-stage novel pipelines including SAL200 to global pharmaceutical companies. In 2018, signed global licensing agreement with Roivant Sciences worth US$667.5M inclusive of milestone payments, with royalties on net sales in low double digits. Active pursuit of out-licensing opportunities for endolysin pipelines and IMPA-based immuno-oncology agents.
  2. Molecular Diagnostics Products: Revenue from development and commercialization of molecular diagnostic kits for animal and human infectious diseases including COVID-19 diagnostic kits, avian influenza tests, and other PCR/qPCR-based diagnostics. Also received CE-IVDR certification for nucleic acid automatic extraction reagent.
  3. Veterinary Antibiotic Alternatives: Commercialized animal antibiotic alternatives using natural bacteriophages to address issues associated with synthetic veterinary antibiotics, generating stable revenue from livestock and aquaculture markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

iNtRON Biotechnology product offering

Product offering

Core offering

iNtRON Biotechnology develops and commercializes bacteriophage- and endolysin-based biopharmaceuticals through two proprietary platform technologies: itLysin® (engineered endolysin therapeutics) and IMPA™ (modular bacteriophage engineering for immunotherapeutics and vaccines). The company also develops and sells the LiliF™ line of molecular diagnostic kits for human and animal infectious diseases and veterinary bacteriophage-based antibiotic alternatives.

Product overview

iNtRON Biotechnology is a novel drug development company operating two core divisions: a New Drug Part focused on biopharmaceutical development, and a DR (Diagnostics & Reagents) Part generating current revenue through molecular diagnostic kits. The New Drug Part centers on two proprietary platform technologies: itLysin®, an engineered endolysin platform for First-in-Class anti-infectives targeting antimicrobial resistance (AMR), and IMPA™, a bacteriophage engineering platform enabling First-in-Concept immunotherapeutics and vaccines for oncology and infectious diseases. The lead pipeline SAL200 [INT-211] has advanced to US FDA Phase 2b for infective endocarditis, while SAL200 [INT-214] nasal decolonization received MFDS Phase 1/2a IND approval. Additional pipelines span CRE decolonization (PKL200), colorectal cancer (TgC-Phage E), GLP-1 delivery (TgG-Phage E), ASF vaccine, and agricultural applications (EAL2200 for fire blight). The company also operates the LiliF™ diagnostic kit brand and holds supporting platforms including PHAGERIA®, PHAGERUS®, and PHAGERIARUS® for microbiome-based immunotherapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • itLysin: Proprietary endolysin engineering platform technology for developing engineered endolysins as smart therapeutics for antimicrobial resistance (AMR)
  • IMPA
  • PHAGERIA
  • PHAGERUS
  • PHAGERIARUS
  • LiliF
  • N-Rephasin

Products and services

  • itLysin® Platform (Engineered Endolysin Therapeutics) Proprietary endolysin-engineering platform that develops engineered bacteriophage-derived lysins enhanced through advanced bio-engineering to overcome superbugs with superior activity, stability, and safety. Targeted at pharmaceutical partners for licensing and clinical co-development.
  • IMPA™ (Intelligent Modular Phage Assembly) Platform Bacteriophage engineering platform that integrates transposon mutagenesis, CRISPR/Cas-based editing, and AI-driven analytics to develop modular phages displaying target proteins on capsids or outer surfaces, enabling dual-targeting therapeutics (bactericidal activity combined with functional protein effects) for immuno-oncology and vaccine applications.
  • SAL200 [INT-211] Drug Candidate Lead itLysin®-derived endolysin drug candidate for treatment of infective endocarditis and bacteremia caused by MRSA, VRSA, and CoNS. Holds US FDA Phase 2b IND approval and demonstrated 67- to 267-fold higher antibacterial activity than competing candidates in University of Barcelona research.
  • SAL200 [INT-214] Nasal Decolonization Drug Candidate Nasal SAL200 formulation for pre-operative Staphylococcus aureus decolonization to prevent hospital-acquired infections. MFDS Phase 1/2a IND approved, with clinical site designated at Seoul National University Hospital.
  • PKL200 [INT-223] CRE Decolonization Drug Candidate Engineered endolysin candidate for intestinal Carbapenem-Resistant Enterobacteriaceae (CRE) decolonization aimed at preventing superbug spread.
  • BAL200 (N-Rephasin®) Anthrax Treatment Endolysin-based biologic for treatment of inhalational anthrax infection by Bacillus anthracis; received US FDA Orphan Drug Designation providing 7-year market exclusivity, tax credits, and fee waivers.
  • TgC-Phage E Colorectal Cancer Therapeutic IMPA™-engineered bacteriophage targeting colorectal cancer-associated bacteria (ETBF and pks+ E. coli) using a dual mechanism of bacterial eradication plus genotoxin neutralization. Preclinical proof-of-concept stage.
  • SSL2200 [INT-262] Bovine Mastitis Treatment Engineered endolysin-based treatment for bovine mastitis providing an antibiotic alternative for livestock veterinary applications.
  • EAL2200 Fire Blight Treatment Candidate Endolysin candidate (EAL2200) for agricultural fire blight prevention and treatment in apple and pear orchards, achieving 100% eradication of all three Erwinia amylovora target strains at 10 μg/mL via an ultra-rapid lytic mechanism. Produced via the Spirulina microalgae platform with 16.5-fold higher productivity than E. coli. Patent filed July 2025.
  • GN200 [INT-001] Gram-Negative Antibacterial Candidate Broad-spectrum gram-negative antibacterial drug candidate targeting resistant gram-negative bacteria for antimicrobial resistance applications.
  • AgASF-Phage E African Swine Fever Vaccine Candidate IMPA™ platform-based vaccine candidate for African Swine Fever, targeted at the global animal health market.
  • TgG-Phage E GLP-1 Agonist Candidate IMPA™ modular phage platform candidate delivering a GLP-1 agonist short peptide for targeted obesity/metabolic disease therapy, demonstrating the platform's extension beyond full-length proteins.
  • pHyal20 (Hyal20-Phage) Drug Delivery Platform Hyaluronidase phage platform (pHyal20) for subcutaneous injection drug delivery enhancement, designed to improve subcutaneous bioavailability.
  • LiliF™ Molecular Diagnostic Kits Brand of molecular diagnostic kits for human and animal infectious disease detection, including the LiliF™ GBN COVID-19 IgG Rapid Kit (lateral flow immunoassay for anti-SARS-CoV-2 IgG antibodies), avian influenza H5/H7/H9 tests, and bovine blackleg detection assays. Distributed directly and through a commercial subsidiary.
  • CE-IVDR Certified Nucleic Acid Extraction Reagent EU CE-IVDR certified reagent for automatic nucleic acid extraction, providing iNtRON a regulatory pathway for diagnostic products into the European Union market.
  • Spirulina (Arthrospira platensis) Recombinant Protein Production Platform Proprietary microalgae-based (Arthrospira platensis / Spirulina) recombinant protein production platform delivering up to 35.3-fold higher yields than conventional E. coli expression, with the additional ability for Spirulina's cell wall to act as natural encapsulation for whole-cell products. Spirulina has US FDA GRAS status.

Companies that use iNtRON Biotechnology

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

iNtRON Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

iNtRON Biotechnology partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • Seoul National University HospitalcoreStrategic or Co-development Partner · 9 June 2026Designated clinical trial site for Phase 1/2a clinical studies of Nasal SAL200 (INT-214) nasal decolonization drug candidate. Company is working closely with the hospital to initiate clinical studies for Staphylococcus aureus decolonization indication.
  • Seoul National University College of Medicine - Cancer Research InstitutecoreStrategic or Co-development Partner · 1 June 2026Research collaboration for IMPA™ phage efficacy studies against colorectal cancer-associated bacteria (ETBF and pks+ E. coli) using human colon organoid models. Study accepted for publication in Scientific Reports journal, demonstrating therapeutic effects of bacteriophages targeting cancer-associated pathogens.
  • Dr. Jangjun Park (Johns Hopkins University)coreStrategic or Co-development Partner · 23 September 2025Recruited anticancer immunology expert from Professor Drew Pardoll's team at Johns Hopkins University. Dr. Park has 25+ years of experience in cancer immunology with publications in Nature, and experience at Arbutus Biopharma and ISU Abxis. Appointed as Executive Director and head of ACI (anticancer immunology) business division to lead clinical development using IMPA™ platform technology.
  • Prof. Hong Bin Kim (Seoul National University Bundang Hospital)coreStrategic or Co-development Partner · 4 June 2025Appointed as Scientific Advisory Board (SAB) Chair for AMR Committee. Prof. Kim is a world-renowned expert in antimicrobial resistance and member of WHO Strategic and Technical Advisory Group on AMR (STAG-AMR). Provides guidance on clinical development and commercialization of itLysin (endolysin) therapeutics.
  • U.S. Army DEVCOM (U.S. Army Combat Capabilities Development Command)coreStrategic or Co-development Partner · 5 September 2023Bacteriophage development project for urinary tract infections (UTI) targeting E. coli in soldiers. Collaboration leverages iNtRON's bacteriophage technology for military healthcare applications. Featured in major news outlets including The Wall Street Journal, Bloomberg, and Clinical Trials Arena.
  • Roivant SciencesflagshipOEM/ Whitelabel/ Licensing Partner · 20 November 2018Global licensing agreement for SAL200, a novel investigational biologic for treatment of antibiotic-resistant staphylococci infections. Deal worth US$667.5M inclusive of milestone payments, with royalties on net sales in low double digits. Includes option for Roivant to license additional anti-Gram-positive endolysin programs (anti-VRE, anti-TB biologics) for up to US$45M each, and first right of offer for anti-Gram-negative platform. Roivant created dedicated subsidiary for global development and commercialization.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

iNtRON Biotechnology competitors and assessment

Company assessment

Emerging players

  • Locus Biosciences: Locus Biosciences develops engineered phage products using CRISPR-Cas3 payloads to target antibiotic-resistant bacteria. While focused more on engineered phage payloads than endolysins, it overlaps with iNtRON's IMPA platform's modular payload concept for dual-action antibacterial therapeutics.
  • Eligo Bioscience: Eligo Bioscience develops engineered phages (eligobiotics) carrying CRISPR payloads to precisely edit microbiome gene expression. It is comparable to iNtRON's IMPA platform in pursuing programmable phage-based precision therapeutics, though with a different delivery mechanism.
  • Micreos: Micreos develops endolysin-based products including Gladskin (over-the-counter endolysin for skin conditions) and food-safety phage products. While more commercial-stage and consumer-facing, it is comparable to iNtRON's endolysin and veterinary phage (SSL2200, EAL2200) product strategies.

Direct peers

  • Adaptive Phage Therapeutics: Adaptive Phage Therapeutics is a clinical-stage phage therapy company focused on personalized phage treatment for antibiotic-resistant bacterial infections, including a partnership with the US Department of Defense for military wound infections. It is a direct peer to iNtRON's bacteriophage programs including the US Army DEVCOM UTI project.
  • ContraFect Corporation: ContraFect is a US-based clinical-stage biotechnology company developing direct lytic agents (endolysins) for serious bacterial infections including MRSA bacteremia. It is the closest direct competitor to iNtRON's SAL200/itLysin platform and the most referenced endolysin peer in the AMR space.
  • BiomX: BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails for indications including inflammatory bowel disease and colorectal cancer-associated bacteria. Its microbiome-phage approach for oncology and infectious diseases overlaps directly with iNtRON's PHAGERIA and TgC-Phage E programs.
  • Armata Pharmaceuticals: Armata Pharmaceuticals develops engineered bacteriophage-based therapies for antibiotic-resistant infections, including Staphylococcus aureus bacteremia. Both Armata and iNtRON compete in phage/endolysin-based antimicrobial therapeutics, making Armata a direct modality peer.

Others

  • Roivant Sciences: Roivant Sciences is the strategic licensing partner that signed the US$667.5M SAL200 deal with iNtRON in 2018. It is included as an ecosystem participant/customer rather than a competitor, but represents the most important commercial relationship for iNtRON's lead asset and a structural reference point for any future platform out-licensing transactions.

Regional players

  • Pherecydes Pharma: Pherecydes Pharma is a French clinical-stage company developing phage therapy for resistant bacterial infections, including bone-and-joint and burn wound infections. It is a regional (European) phage therapy peer that competes in similar indications to some iNtRON programs.
  • Seegene: Seegene is a major South Korean molecular diagnostics company specializing in multiplex PCR-based diagnostic kits, directly comparable to iNtRON's LiliF molecular diagnostic product line for infectious diseases. Same geography (Korea) and same core technology (PCR/qPCR diagnostics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iNtRON Biotechnology social profiles

Digital presence

iNtRON Biotechnology compliance and trust

Trust signal

Compliance3 records

iNtRON Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iNtRON Biotechnology leadership team

Management profile

Number of profiles

Profiles5 records

iNtRON Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iNtRON Biotechnology M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iNtRON Biotechnology

What does iNtRON Biotechnology do?

iNtRON Biotechnology develops and commercializes bacteriophage- and endolysin-based biopharmaceuticals through two proprietary platform technologies: itLysin® (engineered endolysin therapeutics) and IMPA™ (modular bacteriophage engineering for immunotherapeutics and vaccines). The company also develops and sells the LiliF™ line of molecular diagnostic kits for human and animal infectious diseases and veterinary bacteriophage-based antibiotic alternatives.

Is iNtRON Biotechnology a public or private company?

iNtRON Biotechnology is a public company. It is classified as public and is currently operating.

When was iNtRON Biotechnology founded?

iNtRON Biotechnology was founded in 2000. It employs 51 to 100 people.

Where is iNtRON Biotechnology based?

iNtRON Biotechnology is headquartered in Seongnam, South Korea, in the Asia region.

How does iNtRON Biotechnology make money?

Three revenue lines are on record. Licensing and Royalties are the primary driver. The others are molecular Diagnostics Products and veterinary Antibiotic Alternatives.

Who are iNtRON Biotechnology's main competitors?

Emerging players on record are Locus Biosciences, Eligo Bioscience and Micreos. Direct peers are Adaptive Phage Therapeutics, ContraFect Corporation, BiomX and Armata Pharmaceuticals. Roivant Sciences is listed as an others. Regional players are Pherecydes Pharma and Seegene.

Does iNtRON Biotechnology have an API?

No public API is recorded for iNtRON Biotechnology.

What industry is iNtRON Biotechnology in?

iNtRON Biotechnology's product category is Biopharmaceuticals — Bacteriophage and Endolysin Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireiNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing TechnologyiNtRON Bio filed two patent applications for its IMPA™ gene editing technology utilizing CRISPR-Cas9 and recombination-based methods targeting Pasteurella bacteriophages, reportedly representing the first-ever successful gene editing of these bacteriophages globally. The technology leverages AI-driven analysis and an integrated database containing over 11,000 bacteriophage records and more than 600 whole genome sequences to develop modular phages capable of loading multiple payloads for anticancer drug and vaccine development. The company plans to expand the platform to gene editing of bacteriophages infecting other bacteria to discover and select more effective drug candidates, including ADC drugs and vaccines.PR NewswireiNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent ApplicationiNtRON Bio has successfully validated its IMPA™ phage engineering technology by loading a colibactin-degrading protein onto bacteriophages to create a dual-target therapeutic approach for colorectal cancer, simultaneously eliminating pks+ E. coli bacteria and neutralizing the cancer-causing toxin they secrete. The company has filed a US patent application for this new drug candidate and demonstrated proof-of-concept through preclinical studies. Looking ahead, iNtRON Bio plans to proceed with preclinical proof-of-concept testing and expand IMPA™ technology applications to ADC drug development, anti-cancer agents, and vaccines.PR NewswireiNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technologyiNtRON Biotechnology announced the development of PHAGERIA®, an anti-cancer candidate with enhanced antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe associated with colorectal cancer. The company employed its proprietary Robot Bacteriophage 2nd generation technology combined with in-vitro evolution technology and CRISPR/Cas gene editing to develop the candidate, representing the first application of in-vitro evolution technology to ETBF bacteriophages. iNtRON plans to expand this technology to other bacteriophages to improve antimicrobial properties against harmful gut microbiomes and further advance its bacteriophage-based drug development platform.PR NewswireiNtRON identifies Prophage and Jamphage in the Pancreatic cancer related MicrobiomeiNtRON Biotechnology announced the identification of Prophage and Jamphage within the microbiome of Alkalihalobacillus clausii, specifically from long-term pancreatic cancer survivors. This discovery supports the company's PHAGERIARUS® development project, which aims to create bacteriophage-derived immune regulators for treating immune disorders and cancer. The identified genetic resources are expected to serve as potential candidates for modulating the immune system to reduce cancer recurrence.PR NewswireiNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesisiNtRON Biotechnology announced the development of 2nd generation Robot Bacteriophage platform technology, incorporating random transposon mutagenesis alongside its existing customized CRISPR/Cas system for bacteriophage engineering. The new forward genetics technology enables identification and removal of non-essential genes, allowing gene insertion into freed genomic spaces to create bacteriophages with desired characteristics and enabling high-throughput screening capabilities. The company plans to apply this platform across its PHAGERUS® antiviral, PHAGERIA® anticancer, and PHAGERIARUS® immunomodulatory agent development programs.PR NewswireiNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® PlatformSouth Korean biotechnology company iNtRON Biotechnology announced the development of its CRISPR/Cas gene editing system customized for the genetic modification of specific bacteria and corresponding bacteriophages, branded as the PHAGERUS® Platform. The technology allows free editing of bacteriophage genes to add new functions and differs from conventional approaches by using a company-developed specific host rather than commonly used hosts like Escherichia coli or Streptococcus pyogenes. iNtRON plans to leverage the platform to develop antiviral cocktail agents using natural bacteriophages and validate SARS-CoV-2 vaccine candidates by presenting mimotopes on engineered Mockup-PHAGERUS® constructs.